Cover Image

Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2)

Abstract Antibody therapeutics can be associated with unwanted immune responses resulting in the development of anti‐drug antibodies (ADA). Optimal methods to evaluate the potential effects of ADA on clinical outcomes in oncology are not well established. In this study, we assessed efficacy and safe...

Full description

Saved in:

Bibliographic Details
Main Authors:	Solange Peters (Author), Peter R. Galle (Author), Coen A. Bernaards (Author), Marcus Ballinger (Author), René Bruno (Author), Valerie Quarmby (Author), Jane Ruppel (Author), Alexandr Vilimovskij (Author), Benjamin Wu (Author), Nitzan Sternheim (Author), Martin Reck (Author)
Format:	Book
Published:	Wiley, 2022-01-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1)
by: Benjamin Wu, et al.
Published: (2022)

Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition-overall survival modeling framework
by: Phyllis Chan, et al.
Published: (2021)

Allelic variation in HLA‐DRB1 is associated with development of antidrug antibodies in cancer patients treated with atezolizumab that are neutralizing in vitro
by: Christian Hammer, et al.
Published: (2022)

Pan‐cancer population pharmacokinetics and exposure‐safety and ‐efficacy analyses of atezolizumab in patients with high tumor mutational burden
by: Colby S. Shemesh, et al.
Published: (2020)

Pustular psoriasis triggered by therapy with atezolizumab and bevacizumab
by: Mariani Magnus da Luz Andrade, et al.
Published: (2024)

A case of urticarial vasculitis associated with atezolizumab
by: Jade N. Young, BS, et al.
Published: (2024)

Evaluation of cardiovascular toxicity of the atezolizumab and bevacizumab combination
by: Takahiro Niimura, et al.
Published: (2023)

Downstaging with atezolizumab-bevacizumab: a case series
by: Anand V. Kulkarni, et al.
Published: (2024)

A Rare Case Presentation of Vitiligo Associated With Atezolizumab
by: Kemnasom Nwanwene MD, et al.
Published: (2023)

Cure can be achieved by conversion to microwave ablation following atezolizumab-bevacizumab therapy in unresectable hepatocellular carcinoma
by: Rene John D. Febro, et al.
Published: (2024)

Macular‐type cutaneous adverse reaction due to atezolizumab and pembrolizumab
by: Hitomi Sugino, et al.
Published: (2022)

Product review on the Anti-PD-L1 antibody atezolizumab
by: Neil J. Shah, et al.
Published: (2018)

Cost-effectiveness analysis of atezolizumab in advanced triple-negative breast cancer
by: Lee Cheng Phua, et al.
Published: (2020)

A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
by: Yukinobu Watanabe MD, PhD, et al.
Published: (2021)

Tumor Time‐Course Predicts Overall Survival in Non‐Small Cell Lung Cancer Patients Treated with Atezolizumab: Dependency on Follow‐Up Time
by: Ida Netterberg, et al.
Published: (2020)

Comparison of two‐stage and joint TGI‐OS modeling using data from six atezolizumab clinical studies in patients with metastatic non‐small cell lung cancer
by: Antonio Gonçalves, et al.
Published: (2024)

notch3 is essential for oligodendrocyte development and vascular integrity in zebrafish
by: Andreas Zaucker, et al.
Published: (2013)

Linear IgA bullous dermatosis induced by atezolizumab: a case report
by: Seba Almutairi, et al.
Published: (2024)

Safety and efficacy of atezolizumab in the treatment of cancers: a systematic review and pooled-analysis
by: Tie Y, et al.
Published: (2019)

Atezolizumab-Induced Bell's Palsy in a Patient With Small Cell Lung Cancer
by: Asim Kichloo MD, et al.
Published: (2020)

Immunogenicity of Hydrolysate Formulas in Children (Part 1). Review of 202 Reactions
by: Arnaldo Cantani
Published: (2015)

Effectiveness and safety of atezolizumab, nivolumab and pembrolizumab in metastatic non-small cell lung cancer
by: Amparo Burgos-San José, et al.
Published: (2021)

Comparison of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma with portal vein tumor thrombosis
by: Jeayeon Park, et al.
Published: (2024)

Feasibility of additional radiotherapy in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab
by: Tae Hyun Kim, et al.
Published: (2023)

Development of a pediatric physiologically-based pharmacokinetic model to support recommended dosing of atezolizumab in children with solid tumors
by: Weize Huang, et al.
Published: (2022)

Atezolizumab-Induced Stevens-Johnson Syndrome in a Patient with Non-Small Cell Lung Carcinoma
by: Phatcharawat Chirasuthat, et al.
Published: (2018)

Atezolizumab Plus Bevacizumab-induced Recalcitrant Pyoderma Gangrenosum Treated with Baricitinib: A Case Report
by: Han Seul Kim, et al.
Published: (2023)

A case of de novo psoriasis induced by atezolizumab in a patient with advanced lung cancer
by: Shigeruko Iijima, et al.
Published: (2019)

Killing a fly with a sledgehammer: Atezolizumab exposure in real‐world lung cancer patients
by: Sophie Marolleau, et al.
Published: (2023)

Economic Evaluation of First-Line Atezolizumab for Extensive-Stage Small-Cell Lung Cancer in the US
by: Yingcheng Wang, et al.
Published: (2021)

Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives
by: Facchinetti F, et al.
Published: (2018)

Pharmacoeconomic analysis of atezolizumab plus nab-paclitaxel in the treatment of the advanced or metastatic triple-negative breast cancer
by: A S Kolbin, et al.
Published: (2020)

Letter regarding "Feasibility of additional radiotherapy in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab"
by: Sun Hyun Bae, et al.
Published: (2023)

Triple negative metaplastic breast carcinoma presenting in the background of atypical microglandular adenosis with candidacy for atezolizumab immunotherapy
by: Hector Chavarria, et al.
Published: (2020)

Hyperprogression in a Patient With Hepatocellular Cancer Treated With Atezolizumab and Bevacizumab: A Case Report and Review of Literature
by: Balraj Singh MD, et al.
Published: (2021)

Integrating real‐world data and machine learning: A framework to assess covariate importance in real‐world use of alternative intravenous dosing regimens for atezolizumab
by: Bianca Vora, et al.
Published: (2024)

Complete response in hepatocellular carcinoma with lymph node metastasis by combination therapy of atezolizumab and bevacizumab: a case report
by: Sang Youn Hwang, et al.
Published: (2021)

Favorable response of hepatocellular carcinoma with portal vein tumor thrombosis after radiotherapy combined with atezolizumab plus bevacizumab
by: Yong Tae Kim, et al.
Published: (2023)

Atezolizumab plus platinum-based chemotherapy as first-line therapy for metastatic urothelial cancer: A cost-effectiveness analysis
by: Xiaoyan Liu, et al.
Published: (2022)

Atezolizumab plus bevacizumab and chemotherapy versus bevacizumab plus chemotherapy for metastatic cervical cancer: a cost-effectiveness analysis
by: Hongfu Cai, et al.
Published: (2024)